Vasileios Boulougouris1, Anna Castañé, Trevor W Robbins. 1. Department of Experimental Psychology, Behavioral and Clinical Neuroscience Institute (BCNI), University of Cambridge, Downing Street, CB23EB Cambridge, UK. vb257@cam.ac.uk
Abstract
RATIONALE: Dopamine is strongly implicated in the ability to shift behavior in response to changing stimulus-reward contingencies. OBJECTIVES: We investigated the effects of systemic administration of the D2/D3 receptor agonist quinpirole (0.1, 0.3 mg/kg), the D2/D3 receptor antagonist raclopride (0.1, 0.3 mg/kg), the selective D3 antagonist nafadotride (0.3, 1.0 mg/kg), and combined administration of raclopride (0.1 mg/kg) or nafadotride (1.0 mg/kg) with quinpirole (0.3 mg/kg) on spatial discrimination and reversal learning. MATERIALS AND METHODS: Rats were trained on an instrumental two-lever spatial discrimination and reversal learning task. Both levers were presented, only one of which was reinforced. The rat was required to respond on the reinforced lever under a fixed ratio 3 schedule of reinforcement. Following attainment of criterion, a reversal was introduced. RESULTS: None of the drugs altered performance during retention of the previously reinforced contingencies. Quinpirole (0.3 mg/kg) significantly impaired reversal learning by increasing both trials and incorrect responses to criterion in reversal phase, a pattern of behavior manifested as increased perseverative responding on the previously reinforced lever. In contrast, neither raclopride nor nafadotride when administered alone altered reversal performance. However, raclopride blocked the quinpirole-induced reversal deficit, whereas combined administration of nafadotride and quinpirole affected not only performance during the reversal but also the retention phase. The reversal impairment resulting from co-administration of nafadotride and quinpirole was associated with both perseverative and learning errors. CONCLUSIONS: Our data indicate distinct roles for D2 and D3 receptors in the capacity to modify behavior flexibly in the face of environmental change.
RATIONALE: Dopamine is strongly implicated in the ability to shift behavior in response to changing stimulus-reward contingencies. OBJECTIVES: We investigated the effects of systemic administration of the D2/D3 receptor agonist quinpirole (0.1, 0.3 mg/kg), the D2/D3 receptor antagonist raclopride (0.1, 0.3 mg/kg), the selective D3 antagonist nafadotride (0.3, 1.0 mg/kg), and combined administration of raclopride (0.1 mg/kg) or nafadotride (1.0 mg/kg) with quinpirole (0.3 mg/kg) on spatial discrimination and reversal learning. MATERIALS AND METHODS: Rats were trained on an instrumental two-lever spatial discrimination and reversal learning task. Both levers were presented, only one of which was reinforced. The rat was required to respond on the reinforced lever under a fixed ratio 3 schedule of reinforcement. Following attainment of criterion, a reversal was introduced. RESULTS: None of the drugs altered performance during retention of the previously reinforced contingencies. Quinpirole (0.3 mg/kg) significantly impaired reversal learning by increasing both trials and incorrect responses to criterion in reversal phase, a pattern of behavior manifested as increased perseverative responding on the previously reinforced lever. In contrast, neither raclopride nor nafadotride when administered alone altered reversal performance. However, raclopride blocked the quinpirole-induced reversal deficit, whereas combined administration of nafadotride and quinpirole affected not only performance during the reversal but also the retention phase. The reversal impairment resulting from co-administration of nafadotride and quinpirole was associated with both perseverative and learning errors. CONCLUSIONS: Our data indicate distinct roles for D2 and D3 receptors in the capacity to modify behavior flexibly in the face of environmental change.
Authors: Jamilja A J van der Meulen; Ruud N J M A Joosten; Jan P C de Bruin; Matthijs G P Feenstra Journal: Cereb Cortex Date: 2006-08-18 Impact factor: 5.357
Authors: Alicia Izquierdo; Lisa M Wiedholz; Rachel A Millstein; Rebecca J Yang; Timothy J Bussey; Lisa M Saksida; Andrew Holmes Journal: Behav Brain Res Date: 2006-05-19 Impact factor: 3.332
Authors: Milena Girotti; Samantha M Adler; Sarah E Bulin; Elizabeth A Fucich; Denisse Paredes; David A Morilak Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2017-07-06 Impact factor: 5.067
Authors: Gregory T Collins; Alyssa R Cunningham; Jianyong Chen; Shaomeng Wang; Amy H Newman; James H Woods Journal: Psychopharmacology (Berl) Date: 2011-06-24 Impact factor: 4.530
Authors: Patrick S Johnson; Gregory J Madden; Adam T Brewer; Jonathan W Pinkston; Stephen C Fowler Journal: Psychopharmacology (Berl) Date: 2010-09-04 Impact factor: 4.530
Authors: Jared W Young; J David Jentsch; Timothy J Bussey; Tanya L Wallace; Daniel M Hutcheson Journal: Neurosci Biobehav Rev Date: 2012-10-12 Impact factor: 8.989
Authors: Susanne Graef; Guido Biele; Lea K Krugel; Frank Marzinzik; Michael Wahl; Johann Wotka; Fabian Klostermann; Hauke R Heekeren Journal: Front Hum Neurosci Date: 2010-10-14 Impact factor: 3.169